Adicet Bio gets fast track designation for ADI-270 to treat ccRCC

Adicet Bio announced the U.S. Food and Drug Administration or FDA, has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma or ccRCC, who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor. “We are pleased that ADI-270, our first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors, has been granted Fast Track Designation by the FDA,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “ccRCC is the most common type of kidney cancer, and this significant milestone underscores our commitment to advancing innovative treatments to these patients as quickly as possible.” Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.